Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study

Retina

Volumn 26, Issue 3, 2006, Pages 279-284

  Iturralde, Diana ^a   Spaide, Richard F ^a,b   Meyerle, Catherine B ^a   Klancnik, Jay M ^a   Yannuzzi, Lawrence A ^a   Fisher, Yale L ^a   Sorenson, John ^a   Slakter, Jason S ^a   Freund, K Bailey ^a   Cooney, Michael ^a   Fine, Howard F ^a  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b NONE   (United States)

Author keywords

Bevacizumab; Central retinal vein occlusion; Fluorescein angiography; Macular edema; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; FOLLOW UP; HUMAN; INFLAMMATION; INTRAOCULAR HYPERTENSION; IRIS RUBEOSIS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA TEAR; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; VISUAL ACUITY; FLUORESCENCE ANGIOGRAPHY; IMMUNOLOGY; INJECTION; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VITREOUS BODY;

AGED; ANTIBODIES, MONOCLONAL; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; OPHTHALMOSCOPY; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33646446084     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200603000-00005     Document Type: Article

References (22)

1. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-474.
2. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136.
3. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.
4. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139:860-866.
5. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005;83:71-75.
6. Tewari HK, Sony P, Chawla R, et al. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders. Eur J Ophthalmol 2005;15:619-626.
7. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25:846-850.
8. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
9. Jonas J, Heatley G, Spaide R, Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 2005;14:168-171.
10. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004;137:758-760.
11. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139:993-998.
12. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
13. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
14. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416.
15. Bhisitkul RB, Robinson GS, Moulton RS, et al. An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization. Arch Ophthalmol 2005;123:214-219.
16. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
17. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828.
18. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1645.
19. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
20. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271.
21. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
22. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:13-19.